Literature DB >> 30838641

Advanced oxidation protein products play critical roles in liver diseases.

Yalei Zhao1,2, Lingjian Zhang1,2, Xiaoxi Ouyang1,2, Zhengyi Jiang1,2, Zhongyang Xie1,2, Linxiao Fan1,2, Danhua Zhu1,2, Lanjuan Li1,2.   

Abstract

There is a complex oxidant and antioxidant system that maintains the redox homoeostasis in the liver. While suffering from exogenous or endogenous risk factors, the balance between oxidants and antioxidants is disturbed and excessive reactive oxygen species are generated, resulting in oxidative stress. Oxidative stress is prevalent in various liver diseases and is thought to be involved in their pathophysiology. Advanced oxidation protein products are generated under conditions of oxidative damage and are newly described protein markers of oxidative stress. Previous studies have underscored the universal pathogenic roles of oxidation protein products in various diseases. However, investigations into how these products participate in the development of liver diseases have been superficial and insufficient. In this review, we highlight the current understanding of the roles of advanced oxidation protein products in liver disease pathogenesis and the underlying mechanisms. Moreover, we summarize the current studies on advanced oxidation protein products in infectious and noninfectious, acute and chronic liver diseases. Different strategies for targeting these advanced oxidation protein products and future perspectives, which may pave the way for developing new therapeutic strategies, will also be discussed here.
© 2019 Stichting European Society for Clinical Investigation Journal Foundation.

Entities:  

Keywords:  advanced oxidation protein products; cell cycle; epithelia-mesenchymal transition; liver injury; oxidative stress

Year:  2019        PMID: 30838641     DOI: 10.1111/eci.13098

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  8 in total

1.  Reduction of Hepatic Steatosis, Oxidative Stress, Inflammation, Ballooning and Insulin Resistance After Therapy with Safranal in NAFLD Animal Model: A New Approach.

Authors:  Usman Sabir; Hafiz Muhammad Irfan; Aman Ullah; Yusuf S Althobaiti; Mulazim Hussain Asim
Journal:  J Inflamm Res       Date:  2022-02-24

2.  Baicalin provides protection against fluoxetine-induced hepatotoxicity by modulation of oxidative stress and inflammation.

Authors:  Risha Ganguly; Ramesh Kumar; Abhay K Pandey
Journal:  World J Hepatol       Date:  2022-04-27

3.  Evaluation of Levels of Advanced Oxidative Protein Products in Patients with Polycystic Ovary Syndrome with and without Chronic Periodontitis: A Cross-Sectional Study.

Authors:  Smriti Dharuman; Supraja Ajith Kumar; Subbusamy Kanakasabapathy Balaji; Usha Vishwanath; Royapuram Parthasarathy Parameshwari; Muthukumar Santhanakrishnan
Journal:  Int J Fertil Steril       Date:  2022-01

4.  Association of Higher Advanced Oxidation Protein Products (AOPPs) Levels in Patients with Diabetic and Hypertensive Nephropathy.

Authors:  Giovanni Conti; Daniela Caccamo; Rossella Siligato; Guido Gembillo; Ersilia Satta; Dario Pazzano; Nicolina Carucci; Antonio Carella; Giuliana Del Campo; Antonino Salvo; Domenico Santoro
Journal:  Medicina (Kaunas)       Date:  2019-10-07       Impact factor: 2.430

5.  Advanced Oxidation Protein Product Promotes Oxidative Accentuation in Renal Epithelial Cells via the Soluble (Pro)renin Receptor-Mediated Intrarenal Renin-Angiotensin System and Nox4-H2O2 Signaling.

Authors:  Kai Xue; Yurong Wang; Yan Wang; Hui Fang
Journal:  Oxid Med Cell Longev       Date:  2021-11-26       Impact factor: 6.543

6.  Curcumin as a Therapeutic Strategy in Liver Diseases.

Authors:  Rita Rezzani; Caterina Franco; Luigi Fabrizio Rodella
Journal:  Nutrients       Date:  2019-10-17       Impact factor: 5.717

7.  Using advanced oxidation protein products and ischaemia-modified albumin to monitor oxidative stress levels in patients with drug-induced liver injury.

Authors:  Lan-Lan Xiao; Fen Zhang; Ya-Lei Zhao; Ling-Jian Zhang; Zhong-Yang Xie; Kai-Zhou Huang; Xiao-Xi Ouyang; Xiao-Xin Wu; Xiao-Wei Xu; Lan-Juan Li
Journal:  Sci Rep       Date:  2020-10-22       Impact factor: 4.379

8.  Lack of Type I Interferon Signaling Ameliorates Respiratory Syncytial Virus-Induced Lung Inflammation and Restores Antioxidant Defenses.

Authors:  Maria Ansar; Yue Qu; Teodora Ivanciuc; Roberto P Garofalo; Antonella Casola
Journal:  Antioxidants (Basel)       Date:  2021-12-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.